SCHEMBL256045

SCHEMBL256045

CC/C=C/c1cccn1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.52
TRIM33 Q9UPN9 1/20 0.52
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
KMT2A Q03164 8/20 0.40
MAPT P10636 8/20 0.40
MEN1 O00255 6/20 0.40
TDP1 Q9NUW8 4/20 0.40
USP2 O75604 3/20 0.40
GAA P10253 3/20 0.40
TLR9 Q9NR96 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
KDM4E B2RXH2 3/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22182585 1.00 TRIM24 (0.52) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL15871031 0.82 TRIM24 (0.65) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL10742280 0.82 TRIM24 (0.50) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL21782323 0.82 TRIM24 (0.50) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL10742284 0.82 TRIM24 (0.50) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL6762457 0.80
SCHEMBL18270126 0.79 TRIM24 (0.47) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL16770286 0.78 TRIM24 (0.60) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL16770285 0.78 TRIM24 (0.60) TRIM24TRIM33ALDH1A1SMN1; SMN2KMT2A
SCHEMBL10178210 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121292-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2017-05-04 US disclosed
EP-2611300-B1 SUBSTITUTED ANNELATED DIHYDROPYRIMIDINONE COMPOUNDS BAYER IP GMBH (DE) 2016-04-06 EP disclosed
WO-2012028578-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER CROPSCIENCE AG (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121292-A1 HIV REPLICATION INHIBITING PYRIMIDINES RRM2B, CCNO, RRM2 TRIM24 1615/4885TRIM33 873/4885ALDH1A1 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.